Analysis of antiviral use efficiency criteria in the complex pharmacotherapy of community acquired pneumonia

Analysis of antiviral use efficiency criteria in the complex pharmacotherapy of community acquired pneumonia

According to modern view, bacterial pathogens are the leading and most common cause of community-acquired pneumonia (CAP), but at the same time the results of numerous microbiological studies conducted in recent years showed that viruses confidently play the next leading role of CAP causes. Today, a...

Full description

Bibliographic Details
Main Authors:	S. O. Soloviov, I. V. Dziublyk, V. V. Trokhymchuk
Format:	Article
Language:	Ukrainian
Published:	The State Expert Center of the Ministry of Health of Ukraine 2019-03-01
Series:	Фармацевтичний журнал
Subjects:	community acquired pneumonia pharmacotherapy pentanedioic acid іmidazolyl ethanamide clinical and laboratory indicator
Online Access:	https://pharmj.org.ua/index.php/journal/article/view/238/210

Similar Items

Pharmacoeconomic research of pharmacotherapy schemes of community-acquired pneumonia with the inclusion of antiviral drugs
by: S. O. Soloviov, et al.
Published: (2020-03-01)

Method of quality improvement and economic efficiency of pharmacotherapy for community-acquired pneumonia and its utility in Ukraine health-care facilities
by: A.B. Zimenkovsky
Published: (2020-09-01)

Optimizing antibiotic therapy of group IV community-acquired pneumonia patients
by: Dziublyk Ya.O.
Published: (2014-06-01)

2-Amino-6-chloropyridine–glutaric acid (1/1)
by: R. Manickam, et al.
Published: (2019-06-01)

Features of laboratory indicators of severe community-acquired pneumonia
by: Pertzeva T.A., et al.
Published: (2017-06-01)

Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
by: V. G. Deriushkin, et al.
Published: (2021-02-01)

Community-acquired pneumonia /
by: Suttorp, N. (Norbert), 1953-, et al.
Published: (2007)

Community-Acquired Pneumonia: a Comparison between elderly and nonelderly patients
by: S. Jafari, et al.
Published: (2006-08-01)

Problems and solutions on issues of medical care quality in community-acquired pneumonia in hospitals of Saratov region
by: Lotsmanov Yu.F., et al.
Published: (2011-06-01)

Analysis of the effectiveness of physical rehabilitation according spirographic indicators in community-acquired pneumonia during convalescence
by: Y. S. Kalmykova, et al.
Published: (2014-09-01)

Evaluation of mutagenicity, genotoxicity and chronic toxicity of antiviral drug imidazolyl ethanamide pentandioic acid in <i>in vitro</i> and <i>in vivo</i> test systems
by: E. A. Jain, et al.
Published: (2021-11-01)

Тhe features of severe community acquired pneumonia
by: Avramenko I.V.
Published: (2015-06-01)

Hospital Acquired Pneumonia
by: Halis AKALIN, et al.
Published: (1999-12-01)

Dilemma of community-acquired pneumonia
by: Lamia H Shaaban
Published: (2019-01-01)

Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis
by: I. A. Narkevich, et al.
Published: (2019-01-01)

chlamydia pneumoniae unfection in - patients with community acquired pneumonia in Iraq
by: hayfaa D. Salman
Published: (2009-01-01)

Mycoplasma pneumonia and Chlamydia pneumonia infection in patients admitted to Beheshti Hospital in Kashan with community-acquired pneumonia
by: Mansoreh Momen Heravi, et al.
Published: (2023-12-01)

DIAGNOSTIC VALUE OF PROCALCITONIN, C-REACTIVE PROTEIN AND TRANS-RESONANT FUNCTIONAL TOPOGRAPHY IN THE COURSE OF COMMUNITY-ACQUIRED PNEUMONIA
by: A.V. Konkov, et al.
Published: (2008-09-01)

Community-acquired pneumonia in inpatients during the epidemic of the new coronivarus infection of COVID-19
by: V.I. Trykhlib, et al.
Published: (2021-06-01)

Cytokine profile in community-acquired pneumonia in children
by: N. V. Iziurova, et al.
Published: (2022-11-01)

Role and place of levofloxacin in the treatment of community-acquired pneumonia
by: D V Dmytriiev, et al.
Published: (2021-03-01)

Nonlinear main components of the cytokine profile in children with community-acquired pneumonia
by: N. V. Iziurova, et al.
Published: (2024-01-01)

Tigecycline and Community-Acquired Pneumonia
by: Sercan ULUSOY
Published: (2013-12-01)

PES Pathogens in Severe Community-Acquired Pneumonia
by: Catia Cillóniz, et al.
Published: (2019-02-01)

Pattern of community and hospital acquired pneumonia in Egyptian military hospitals
by: Magdy Mohammad Khalil, et al.
Published: (2013-01-01)

Incidence of Antibiotic Treatment Failure in Patients with Nursing Home-Acquired Pneumonia and Community Acquired Pneumonia
by: Mariana Lopes, et al.
Published: (2021-01-01)

Prehospital Period in Patients with COVID-19: Cardiovascular Comorbidity and Pharmacotherapy During the First Epidemic Wave (Hospital Registry Data)
by: S. Yu. Martsevich, et al.
Published: (2022-01-01)

Mycoplasma pneumoniae: Atypical Pathogen in Community Acquired Pneumonia
by: Abdul-Rahman Mamdouh Mohammad, et al.
Published: (2020-12-01)

Scored minor criteria for severe community-acquired pneumonia predicted better
by: Qi Guo, et al.
Published: (2019-01-01)

MODERN ANTIBACTERIAL THERAPY IN HOSPITAL-ACQUIRED PNEUMONIA
by: V. B. Beloborodov, et al.
Published: (2017-11-01)

Hemogram values in community acquired pneumonia
by: Lamiaa H. Shaaban, et al.
Published: (2015-07-01)

An unusual cause of community-acquired pneumonia
by: Jaimie Mittal, et al.
Published: (2018-01-01)

Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
by: Catia Cillóniz, et al.
Published: (2018-04-01)

The effect of taking antibacterial therapy on the outpatient stage and outcomes of community-acquired pneumonia in Tomsk hospitals
by: Daria A. Vinokurova, et al.
Published: (2024-01-01)

Etiology of community-acquired pneumonia in the military personnel
by: Speranskaya E.V., et al.
Published: (2018-05-01)

Efficacy of immunovenin in patients with community-acquired pneumonia
by: Usman Raul'evich Farkhutdinov, et al.
Published: (2011-03-01)

The influence of etiological factors on immunoreactivity in patients with community-acquired pneumonia
by: A. V. Rvacheva, et al.
Published: (2018-12-01)

Community acquired paediatric pneumonia; experience from a pneumococcal vaccine- naive population
by: Sanath Thushara Kudagammana, et al.
Published: (2020-08-01)

Community-acquired pneumonia with atypical (mycoplasmic and chlamydial) infection
by: G V Trubnikov, et al.
Published: (2009-03-01)

A case of community acquired pneumonia with Pseudomonas aeruginosa
by: K Jayatilleka, et al.
Published: (2012-08-01)